Literature DB >> 19716320

Impact of comorbid conditions and race/ethnicity on glycemic control among the US population with type 2 diabetes, 1988-1994 to 1999-2004.

Dong-Churl Suh1, In-Sun Choi, Craig Plauschinat, Jinweon Kwon, Michelle Baron.   

Abstract

OBJECTIVE: To measure trends in glycemic control in type 2 diabetes in the United States from 1988-1994 to 1999-2004 and to identify factors influencing glycemic control, including the presence of comorbid conditions and race/ethnicity.
METHODS: Participants in the National Health and Nutrition Examination Surveys (1988-1994 and 1999-2004) aged ≥30 years with diagnosed type 2 diabetes were identified. Outcome measures included glycemic control [glycosylated hemoglobin (A1C) <7%] and pharmacologic treatment rate. Comorbid conditions assessed included obesity, hyperlipidemia, and hypertension.
RESULTS: Prevalence of type 2 diabetes increased from 5.8% in 1988-1994 to 7.1% in 1999-2004. Rates of treatment for type 2 diabetes improved, from 72.3% to 82.2%. The proportion of patients who achieved A1C <7% did not change significantly (44.4% to 50.1%, P=.06); however, blood pressure and cholesterol level both improved. During 1999-2004, only 14% of persons treated for type 2 diabetes did not have an additional comorbid condition; 21% had all three comorbid conditions. During 1999-2004, among treated patients, non-Hispanic blacks were 0.43 times as likely (95% CI 0.29-0.63), and Mexican Americans were 0.47 times as likely (95% CI 0.32-0.68), to have A1C <7% compared to non-Hispanic whites.
CONCLUSIONS: Despite improved treatment rates, one in two individuals with type 2 diabetes has A1C of ≥7%. Most type 2 diabetic subjects also suffer from hypertension, hyperlipidemia, and/or obesity, and glycemic control rates were lowest for those with all three conditions. Non-Hispanic blacks and Mexican Americans are less likely to achieve glycemic control as compared to non-Hispanic whites.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19716320     DOI: 10.1016/j.jdiacomp.2009.07.001

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  25 in total

1.  Role of adenylyl cyclase activator in controlling experimental diabetic nephropathy in rats.

Authors:  Lakhwinder Singh; Surbhi Rana; Sidharth Mehan
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-10-29

Review 2.  Glucose control in diabetes: the impact of racial differences on monitoring and outcomes.

Authors:  Jennifer A Campbell; Rebekah J Walker; Brittany L Smalls; Leonard E Egede
Journal:  Endocrine       Date:  2012-07-20       Impact factor: 3.633

3.  The validity of a patient-reported adverse drug event questionnaire using different recall periods.

Authors:  Sieta T de Vries; Flora M Haaijer-Ruskamp; Dick de Zeeuw; Petra Denig
Journal:  Qual Life Res       Date:  2014-05-22       Impact factor: 4.147

Review 4.  Patients With Type 2 Diabetes: Anesthetic Management in the Ambulatory Setting. Part 1: Pathophysiology and Associated Disease States.

Authors:  Bryant W Cornelius
Journal:  Anesth Prog       Date:  2016

5.  Cardiovascular disease risk factor clustering among African American adults.

Authors:  Meghan Baruth; Sara Wilcox; Brent M Egan; Marsha Dowda; Marilyn Laken; Tatiana Y Warren
Journal:  Ethn Dis       Date:  2011       Impact factor: 1.847

6.  Analysis of sphingolipid composition in human vitreous from control and diabetic individuals.

Authors:  Lynda A Wilmott; Richard C Grambergs; Jeremy C Allegood; Timothy J Lyons; Nawajes Mandal
Journal:  J Diabetes Complications       Date:  2018-12-14       Impact factor: 2.852

7.  Decrease in Glycemic Index Associated with Improved Glycemic Control among Latinos with Type 2 Diabetes.

Authors:  Monica L Wang; Lauren Gellar; Brian H Nathanson; Lori Pbert; Yunsheng Ma; Ira Ockene; Milagros C Rosal
Journal:  J Acad Nutr Diet       Date:  2014-12-26       Impact factor: 4.910

8.  Ethnicity/culture modulates the relationships of the haptoglobin (Hp) 1-1 phenotype with cognitive function in older individuals with type 2 diabetes.

Authors:  Elizabeth Guerrero-Berroa; Ramit Ravona-Springer; Anthony Heymann; James Schmeidler; Hadas Hoffman; Rachel Preiss; Keren Koifmann; Lior Greenbaum; Andrew Levy; Jeremy M Silverman; Derek Leroith; Mary Sano; Michal Schnaider-Beeri
Journal:  Int J Geriatr Psychiatry       Date:  2015-09-21       Impact factor: 3.485

9.  Are individuals with diabetes seeing better?: a long-term epidemiological perspective.

Authors:  Ronald Klein; Barbara E K Klein
Journal:  Diabetes       Date:  2010-08       Impact factor: 9.461

10.  Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis.

Authors:  Faramarz Ismail-Beigi; Manuel S Lombardero; Jorge Escobedo; Saul Genuth; Jennifer Green; Elaine Massaro; Arshag D Mooradian; Fernando Ovalle; Fred Whitehouse; Joel Zonszein
Journal:  J Diabetes Complications       Date:  2013-03-07       Impact factor: 2.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.